Description
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the natural signal produced by the hypothalamus that tells the pituitary gland to release growth hormone.
Research has focused on Tesamorelin because it increases endogenous growth-hormone release and, in turn, raises IGF-1. These signalling systems are involved in fat metabolism, body composition, protein metabolism and tissue maintenance. Tesamorelin has been particularly well studied in relation to visceral abdominal fat and metabolic changes.
In plain English: researchers are interested in Tesamorelin because it encourages the body to release more of its own growth hormone. That has made it especially useful for studying how the growth-hormone/IGF-1 system affects abdominal fat, metabolism and body composition.
Unlike many research peptides, Tesamorelin has a substantial human clinical evidence base. Regulated pharmaceutical Tesamorelin has been approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and controlled trials have shown reductions in visceral fat and improvements in some body-composition measures. It is not approved as a general weight-loss treatment. :chatgpt-content-reference{index=”1″}
Supplied by Black Knight Peptides for laboratory and research purposes only.
Not for human consumption.
